A severe case of human coronavirus 229E pneumonia in an elderly man with diabetes mellitus: a case report

Wen Sun, Ji-Ping Liao, Kun-Yao Yu, Jian-Xing Qiu, Chen-Li Que, Guang-Fa Wang and Jing Ma

Abstract

Background: With pandemic of coronavirus disease 2019 (COVID-19), human coronaviruses (HCoVs) have recently attached worldwide attention as essential pathogens in respiratory infection. HCoV-229E has been described as a rare cause of lower respiratory infection in immunocompetent adults.

Case presentation: We reported a 72-year-old man infected by HCoV-229E with rapid progression to acute respiratory distress syndrome, in conjunction with new onset atrial fibrillation, intensive care unit acquired weakness, and recurrent hospital acquired pneumonia. Clinical and radiological data were continuously collected. The absolute number of peripheral T cells and the level of complement components diminished initially and recovered after 2 months. The patient was successfully treated under intensive support care and discharged from the hospital after 3 months and followed.

Conclusion: HCoV-229E might an essential causative agent of pulmonary inflammation and extensive lung damage. Supportive treatment was essential to HCoVs infection on account of a long duration of immunological recovery in critical HCoV-229E infection.

Keywords: Adult respiratory distress syndrome, Human coronavirus 229E, Immunology, Pneumonia

Background

Human coronaviruses (HCoVs) are enveloped, single-stranded RNA viruses [1]. HCoV-229E, as a cause of the common cold [1], rarely leads to lower respiratory infection in immunocompetent adults. Recently, HCoV infections have attracted the world’s attention due to the coronavirus disease 2019 (COVID-19) pandemic [2].

Herein, we report a case of severe pneumonia caused by HCoV-229E with continuous monitoring of the systemic immune response, and review the literature on HCoV strains.

Case presentation

A 72-year-old man went to the emergency department (day 3) on Nov 4, 2019, with a 3-days history of fever (38.3 °C/100.94 °F), fatigue, myalgia and nonproductive cough, and a 1-day history of dyspnea. In the past 30 years, the patient had diabetes mellitus (DM) with repaglinide and dimethylbiguanide treatment, and obstructive sleep apnoea-hypopnea syndrome treated by nasal septal reconstruction. He had never smoked or drank, was exposed to live poultry or travelled.

His pulse was 122 beats per minute; his respiratory rate was 35 breaths per minute; and his blood pressure was 148/86 mmHg. Auscultation revealed rales in the bilateral basic lung fields. Arterial blood gas analysis showed respiratory alkalosis and respiratory failure type I (pH 7.49; pCO₂: 29 mmHg; pO₂: 43 mmHg; HCO₃⁻: 22.1 mmol/l).

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Laboratory analyses (Fig. 1) revealed lymphopenia, neutrophilia, high C-reactive protein (CRP) levels and elevated lactate dehydrogenase (LDH) levels. Levels of brain natriuretic peptide (248 pg/ml) and cardiac troponin I (0.042 ng/ml) slightly increased. Levels of glycosidic hemoglobin (7.5%, normal range: 4.0 ~ 6.0%), ferritin (729 ng/ml, normal range: 4.0 ~ 20.0 ng/ml) and Interleukin-6 (10.63 pg/ml, normal range: <6.4 pg/ml) increased. D-dimer level on admission were above the normal range (3.65 mg/l), and color doppler ultrasound revealed soleal and gastrocnemius vein thrombosis in both legs. Chest computed tomography (CT) showed diffuse ground-glass opacities (GGOs) with consolidation, pleural effusion, pericardial effusion and lymphadenopathy (Fig. 2). Intravenous moxifloxacin and non-invasive ventilation were given.

He was transferred to the respiratory intensive care unit (RICU, day 4) and received invasive ventilation (day

| Day | FEVER (°C) | Lymphopenia (%) | Neutrophilia (%) | LDH (IU/L) | TRACP (mg/L) | sTAT8 (pg/mL) | Ferritin (ng/mL) | HbA1c (mg/dL) | Interleukin-6 (pg/mL) |
|-----|------------|-----------------|-----------------|------------|-------------|--------------|-----------------|---------------|---------------------|
| Day 4 | 38.5       | 2.0%            | 7.0%            | 400        | 100         | 4.0          | 729             | 6.0           | 10.63               |
| Day 5 | 38.7       | 1.5%            | 7.5%            | 420        | 120         | 4.8          | 729             | 6.0           | 10.63               |
| Day 6 | 38.7       | 1.0%            | 8.0%            | 450        | 150         | 5.0          | 729             | 6.0           | 10.63               |
| Day 7 | 38.7       | 0.5%            | 8.5%            | 470        | 180         | 5.2          | 729             | 6.0           | 10.63               |
| Day 8 | 38.7       | 0.0%            | 9.0%            | 500        | 200         | 5.4          | 729             | 6.0           | 10.63               |

Fig. 1 Time schedule of clinic course and laboratory parameters based on days from symptom onset, from Nov 2 to Nov 20, 2019. *The normal values of parameters were underlined in the figure. BALF, bronchoalveolar lavage fluid; CRAB, carbapenem-resistant Acinetobacter baumannii; ER, emergency room; HCoV-229E: human coronavirus 229E; hsCRP, high sensitive C-reactive protein; MG, intravenous immunoglobulin; LDH, lactate dehydrogenase; MP, methylprednisolone; NIV, non-invasive ventilation; PCT, procalcitonin; PSV, pressure support ventilation; RICU, respiratory intensive care unit; SIMV, synchronized intermittent mandatory ventilation

Fig. 2 Non-contrast enhanced thin-section CT scans on day 4 after symptom onset. a, b Lung window, bilateral ground-glass opacities with clear boundary, multifocal consolidations, air bronchograms, smooth interlobular and intralobular septal thickening could be seen (black triangle). c, d Mediastinum window, lymphadenopathy (white arrow), bilateral pleural effusions (black arrows), and moderate pericardial effusions (curved white arrow) were shown
5) due to rapidly progressing to acute respiratory distress syndrome (ARDS). Fibreoptic bronchoscopy was performed (day 6), the bronchoalveolar lavage fluid (BALF) was bloody with an increased proportion of neutrophils (89%) and eosinophils (2%). Metagenomics next-generation sequencing (mNGS) of BALF found the only pathogen of HCoV-229E (sequence reads: 5195 bp). Culture and smear of lower respiratory tract secretions were negative for bacteria and fungus. Nucleic acid tests for common respiratory virus, mycoplasma and chlamydia were negative. Pleural fluid was sterile transudate dominated by mononuclear cells (62%). Procalcitonin (PCT) increased significantly after endotracheal intubation. Short-term and low-dose methylprednisolone and intravenous immunoglobulin (IVIG) were given. Low molecular weight heparin was given for deep venous thrombosis (DVT). Broad spectrum antibiotics were empirically used (Fig. 1).

On day 8, paroxysmal atrial fibrillation occurred without cardiac structural changes. On day 14, repeated bronchoscopy was performed for increased infiltration in the left upper lobe. Cytological analysis of BALF showed an increased ratio of neutrophils (93%). Culture of BALF was positive for carbapenem-resistant Acinetobacter baumannii, and antibiotics were administered.

On day 19, the patient fulfilled the criteria of withdrawal from mechanical ventilation but failed, due to ICU acquired weakness (ICUAW) and persistent atrial fibrillation. After reintubation, he suffered from ventilator-associated pneumonia. Bacterial culture of lower respiratory tract secretion yielded positive for carbapenem-resistant Klebsiella and methicillin-resistant Staphylococcus aureus. Avibactam-ceftazidime, teicoplanin, or linezolid was successively used, together with a conservative liquid strategy, limb rehabilitation exercise, phrenic nerve stimulation, and nutrition support under

---

**Fig. 3** Non-contrast enhanced coronal-reconstruction CT scans on day 4, day 17, day 60, day 161 and day 265 after symptom onset. a Bilateral diffuse ground-glass opacities with consolidations. b Lung volume reduced associated with reticular and traction bronchiectasis (black arrows) in both lungs and consolidation in the left lower lobe. c Absorption of bilateral pulmonary lesions, focal honeycomb lung in the right upper lobe, coupled with traction bronchiectasis in the left upper lobe. d Further resolution of lesions remaining fewer fibrosis changes in the bilateral lung field. e Absorption of lung fibrosis with a focal pneumothorax in right upper lobe (white arrows).
intensive glucose control. The patient was successfully weaned from ventilation on day 74 and discharged from the hospital on day 105. He remains well during the regular follow-up. Radiographic findings (Fig. 3) showed the development and gradual absorption of fibrosis and recent focal pneumothorax in right upper lobe.

The absolute counts of lymphocyte subsets were measured by flow cytometry in peripheral blood (Fig. 4). The absolute number of CD4\(^+\) and CD8\(^+\) T cells decreased within 1 week and recovered after 45 days, as well as the levels of complements showed the same trend. There were no changes in the proportion of T-helper 1 (Th1) and Th17 cells. The proportion of activated CD4\(^+\) and CD8\(^+\) T cells began to increase after day 10. The proportion of Th2 cells persistently increased from day 10 and lasted for more than 40 days.

**Discussion and conclusions**

HCoV-229E is one of four non-severe acute respiratory syndromes (SARS)-like CoVs (HCoV-NL63, HCoV-229E, HCoV-OC43, and HCoV-HKU1) causing the common cold, and severe lower respiratory infection caused by HCoV-229E is predominantly found in the elderly, children under 2 years of age, and those with immunosuppression from any cause [3–5]. DM was associated with a higher rate of mortality and morbidity in non-SARS-like CoV (HCoV-NL63), and SARS-like CoV (SARS and COVID-19) [6–8]. Hence, we speculated that old age and DM might play a crucial role in the severity of infection in this case.

The prevalence of non-SARS-like CoV-associated ARDS was extremely low in adult (0.1%) [9]. In this case, disease progression in the first 7 days was mainly caused by HCoV-229E because it was the only pathogen, and antibiotic therapy was ineffective. The median duration to ARDS was 4 days, which was quicker than that of COVID-19 [6]. Similar to COVID-19, this patient had all of the factors of a poor prognosis including lymphopenia, neutrophilia, elevated LDH levels, high CRP levels, increased D-dimer and abnormal myocardial indices [6]. Moreover, new onset atrial fibrillation and ICUAW, which were mostly identified in systemic inflammatory response syndrome, might have contributed to the prolonged hospital stay of our patient than that of HCoV-infected patients in a previously long-term study (average, 12 days; range, 5–30 days) [8].

To our knowledge, no researches were available on the continuous image in patients with HCoV-229E pneumonia. The CT chest imaging of our patient manifested as GGOs and consolidations in multiple lobes throughout both lungs, which were the predominant features within 2 weeks, similar to COVID-19 [10]. In addition, mediastinal lymphadenopathy, pleural effusion and pericardial effusion of our patient, which were rare in COVID-19, might be related to viral-induced myocardial damage and exuberant inflammatory response [10, 11]. Elderly patients and those with critical cases of SARS were likely
to develop fibrosis [10, 12]. In our case, fibrosis developed early (day 17), absorbed gradually, and lasted for at least 8 months.

There are no data on the specific role of either humoral or cellular immunity or innate immunity in patients recovering from HCoV-229E. Similar to COVID-19 [6, 13], the initial decrease in the number of lymphocytes and CD4+ and CD8+ T cells in this case might suggest a dysregulated cellular immune response [14]. Low levels of complements were reported to be a risk factor for high mortality in SARS [15]. The proportion of Th17 cells was persistently normal in this patient, albeit with an increased concentration of highly proinflammatory CCR4+CCR6+Th17 cells in COVID-19 [13]. The time to immunological recovery of this case was 2 months when the patient was liable to acquire secondary infections. Thus, we suggest that patients with severe HCoV infection should be closely monitored for over 2 months.

Whether HCoV infection could benefit from corticosteroid therapy has remained controversial. It was illustrated that early corticosteroid treatment could induce higher viral loads and delayed viral clearance [16]. However, recent studies from COVID-19 revealed that the use of corticosteroids was associated with shorter hospitalization stays [17], and reduced 28-day all-cause mortality among critical patients with receiving respiratory support [18, 19]. This case highlighted that low-dose and short-term corticosteroids at an early stage might reduce the excessive inflammatory response.

Currently, there is no definitely effective antivirals for the treatment of coronavirus infection. Efficacy of IVIG for severe HCoV infection needs further evaluation. Experience from our patient emphasized the importance of supportive care strategies as provided in previous recommendations [20], including timely mechanical ventilation, intensive glucose control, rehabilitation, treatment of DVT and secondary infection control.

There were several limitations. First, we lacked detection technology for virus titres. Second, we were not sure when the virus was completely cleared, as the family refused repeated mNGS tests. Third, we did not test the T lymphocyte subset within 1 week.

In conclusion, the case of severe HCoV-229E pneumonia with poor prognostic features indicated the necessity of closely monitoring multiorgan involvement associated with HCoV infection. Suboptimal T cell response and excessive consumption of complement would last for 2 months in severe cases, contributing to a high risk of secondary infection. Supportive therapy should be indispensable for HCoV-229E infection.

**Abbreviations**

ARDS: Acute respiratory distress syndrome; BALF: Bronchoalveolar lavage fluid; COVID-19: Coronavirus disease 2019; CRAB: Carbapenem-resistant Acinetobacter baumannii; DM: Diabetes mellitus; HCoV: Human coronaviruses; CRP: C-reactive protein; CT: Computed tomography; GG0s: Ground-glass opacities; ICUAW: Intensive care unit acquired weakness; IVIG: Intravenous immunoglobulin; LDH: Lactate dehydrogenase; mNGS: Metagenomics next-generation sequencing; PCT: Procalcitonin; RICU: Respiratory intensive care unit; SARS: Severe acute respiratory syndrome; Th: T-helper

**Funding**

This study was supported by Special Research Fund of PKUHSC for Prevention and Control of COVID-19 and the Fundamental Research Funds for the Central Universities (No. BMU2020H1YXZ003). The funders had role in decision to publish and preparation of the manuscript.

**Availability of data and materials**

All the information generated or analyzed during this study are included in the manuscript. There are no datasets related to this case report.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Competing interests**

There are no reported conflicts of interest of relevance to this article.

**Author details**

1. Department of Pulmonary and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China. 2. Department of Radiology, Peking University First Hospital, Beijing 100034, China.

**Received**

4 August 2020 Accepted: 16 May 2021

Published online: 04 June 2021

**References**

1. Corman VM, Baldwin HJ, Tateno AF, Zerbinati RM, Annan A, Owusu M, et al. Evidence for an ancestral association of human coronavirus 229E with bats. J Virol. 2015;89(23):11858–70. https://doi.org/10.1128/JVI.01755-15.
2. Mahase E. Coronavirus: covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020;368:m641. 70. https://doi.org/10.1128/JVI.01755-15.
3. Gaunt ER, Hardie A, Claas EC, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48(8):2940–7. https://doi.org/10.1128/JCM.00636-10.
4. Plotkin SA. The new coronavirus, the current king of China. J Pediatric Infect Dis Soc. 2020;9(1):1–2. https://doi.org/10.1093/jids/pxAA018.
5. Walsh EE, Shin JH, Falsey AR. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J Infect Dis. 2013;208(10):1634–42. https://doi.org/10.1093/infdis/jit089.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. https://doi.org/10.1001/jama.2020.1585.
7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

8. Cabeça TK, Granato C, Belleri N. Epidemiological and clinical features of human coronavirus infections among different subsets of patients. Influenza Other Respir Viruses. 2013;7(6):1040–7. https://doi.org/10.1111/irv.12101.

9. Li D, Wolk DM, Cantor MN. Comparing clinical characteristics of influenza and common coronavirus infections using electronic health records. J Infect Dis. 2020. https://doi.org/10.1093/infdis/jiaa626.

10. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425–34. https://doi.org/10.1016/S1473-3099(20)30086-4.

11. Qureshi NR, Hien TT, Farrar J, Gleeson FV. The radiologic manifestations of H5N1 avian influenza. J Thorac Imaging. 2006;21(4):259–64. https://doi.org/10.1097/01.rti.0000213573.94032.53.

12. Antonio GE, Wong KT, Hui DSC, Wu A, Lee N, Yuen EHY, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003;228(3):810–5. https://doi.org/10.1148/radiol.2283030726.

13. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):329–34. https://doi.org/10.1016/S2213-2600(20)30086-4.

14. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39. https://doi.org/10.1007/s00281-017-0629-x.

15. Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9(5):e01753–18.

16. Lee N, Allen Chan KC, Hui DS, Ng EKO, Wu A, Chiu RWK, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–9. https://doi.org/10.1016/j.jcv.2004.07.006.

17. Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, et al. Treatment of severe acute respiratory syndrome with glucocorticoids: the Guangzhou experience. Chest. 2006;129(6):1441–52. https://doi.org/10.1378/chest.129.6.1441.

18. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, JAC S, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324(13):1330–41.

19. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. https://doi.org/10.1056/NEJMoa2021436.

20. Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020;46(2):315–28. https://doi.org/10.1007/s00134-020-05943-5.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.